Nakken K O, Rytter E, Johannessen S I
Statens senter for epilepsi, Sandvika.
Tidsskr Nor Laegeforen. 1998 Feb 28;118(6):872-4.
Gabapentin is a new antiepileptic drug. Its mechanism of action is not clearly understood, but it seems to differ from that of other antiepileptic drugs. The favourable pharmacokinetic properties of gabapentin make it simple to use. Our preliminary clinical observations with gabapentin at the National Center for Epilepsy are presented. 58 adult patients (mean age 28.9 years), mainly with refractory partial seizures, had gabapentin added to their existing medication. The follow-up period was 6.9 months on average. Only one patient experienced a reduction in seizures of more than 50%, while 25 patients experienced a moderate reduction in seizures (10-50%). The clinical effect was most favourable in patients with secondary generalized tonic-clonic seizures. Gabapentin was well tolerated, and no clinically significant interactions were encountered. Recent observations show that the doses of gabapentin used in our study may have been too low.
加巴喷丁是一种新型抗癫痫药物。其作用机制尚不清楚，但似乎与其他抗癫痫药物不同。加巴喷丁良好的药代动力学特性使其使用简便。本文介绍了我们在国家癫痫中心对加巴喷丁进行的初步临床观察。58例成年患者（平均年龄28.9岁），主要为难治性部分性癫痫发作，在其现有药物治疗基础上加用加巴喷丁。随访期平均为6.9个月。只有1例患者癫痫发作减少超过50%，而25例患者癫痫发作有中度减少（10%-50%）。临床效果在继发性全身强直-阵挛性癫痫发作患者中最为显著。加巴喷丁耐受性良好，未发现有临床意义的相互作用。最近的观察表明，我们研究中使用的加巴喷丁剂量可能过低。
